analyzeportfolio
Nasdaq · Healthcare

Option Care Health, Inc. (OPCH)

As-reported financials and SEC filings for Option Care Health, Inc. The latest annual period is FY2025. The latest reported quarter is Q1 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About Option Care Health, Inc.

Option Care Health, Inc. is an independent provider of home and alternate site infusion services in the United States. It offers infusion therapy, nursing support, and care coordination for patients with complex and chronic medical conditions through a network of pharmacies and ambulatory infusion suites. The company serves patients, managed care organizations, hospitals, physicians, pharmaceutical manufacturers, and health systems by delivering therapies such as anti-infectives, nutrition support, immunoglobulin infusion, and treatments for chronic inflammatory and neurological disorders.

Snapshot

Revenue
$5.65B
Revenue growth (YoY)
13.0%
Net income
$207.6M
Diluted EPS
$1.27
Gross margin
19.3%
Operating margin
6.0%
Net margin
3.7%
FCF margin
3.8%
ROE
15.7%
net income / fiscal-year-end equity
P/E
17.9×
trailing when available, otherwise FY EPS
Market cap
$3.60B
Long-term debt / equity
0.87×
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Option Care Health

  • Revenue grew 13.0% to $5.6B in FY2025, slower than the 16.2% the year before.
  • Operating margin is 6.0% in FY2025, +0.4 pp against 5.5% in FY2021.
  • Most recent quarter Q1 FY2026: revenue $1.4B, up 1.3% from Q1 FY2025.
  • Free cash flow was $217M in FY2025, 3.8% of revenue.
  • Net income fell 2.0% to $208M in FY2025.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Option Care Health’s fundamentals sit among the 558 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin19.3%
5th percentile of 282
Operating margin6.0%
61st percentile of 399
Net margin3.7%
61st percentile of 418
FCF margin3.8%
52nd percentile of 372
Revenue growth (YoY)+13.0%
56th percentile of 538
ROE15.7%
83rd percentile of 473
P/E17.9×
37th percentile of 201
Long-term debt / equity0.87×
74th percentile of 243
Short interest5.26d
59th percentile of 557

Option Care Health’s gross margin of 19.3% ranks in the 5th percentile of the 282 Healthcare companies reporting it.

No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 1 of the superinvestors we track (plus 6 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
1
+6 quant / multi-strat
Initiated / added
5
1 new, 4 added
Reduced / exited
4
2 trimmed, 2 exited
Combined position
$140.8M
reported long value
InvestorAs ofPosition valueSharesChange
Millennium ManagementquantQ2 2026$54.9M2.6MAdded
Point72 Asset ManagementquantQ2 2026$37.8M1.8MAdded
Citadel AdvisorsquantQ2 2026$34.3M1.6MReduced
D. E. ShawquantQ2 2026$6.0M284.2KAdded
AQR Capital ManagementquantQ2 2026$3.6M170.2KAdded
Bridgewater AssociatesQ2 2026$2.3M110.3KNew
Two Sigma InvestmentsquantQ2 2026$2.0M97.6KReduced

No longer held by: Duquesne Family Office (as of Q2 2026), Renaissance Technologies (as of Q2 2026)

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
0
Reported activity
Quiet
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-05-07
SULLIVAN TIMOTHY PDirectorBuy24.2K$20.69$500K
2026-05-04
filed 2026-05-05
KRAEMER HARRY M JANSEN JRDirectorBuy36.6K$21.41$784K
2026-05-04
Sethna MeenalChief Financial OfficerBuy16.2K$20.16$327K
2026-05-04
RADEMACHER JOHN CHARLESChief Executive OfficerBuy12.5K$21.18$265K

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
12.0M
settled 2026-08-14
Change vs prior
-7.5%
vs previous settlement
Days to cover
5.26
at avg daily volume
Avg daily volume
2.3M
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-1412.0M-7.5%5.26
2026-07-3113.0M-3.4%4.74
2026-07-1513.5M+1.8%6.53
2026-06-3013.2M+8.1%4.67
2026-06-1512.2M-2.7%4.12
2026-05-2912.6M-15.7%3.85
2026-05-1514.9M+36.4%2.80
2026-04-3010.9M-5.5%3.60

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$5.65B$5.00B$4.30B$3.87B$3.44B
Gross profit$1.09B$1.01B$981.2M$791.2M$779.6M
Operating income$337.9M$321.8M$314.6M$240.2M$190.8M
Net income$207.6M$211.8M$267.1M$150.6M$139.9M
Diluted EPS$1.27$1.23$1.48$0.83$0.77

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$258.4M$323.4M$371.3M$267.5M$208.6M
Capital expenditure$41.3M$35.6M$41.9M$35.4M$25.6M
Free cash flow$217.1M$287.8M$329.4M$232.2M$182.9M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q1 FY2026$1.35B1.3%$45.3M$0.29
Q4 FY2025$1.47B8.8%$58.5M$0.37
Q3 FY2025$1.44B12.2%$51.8M$0.32
Q2 FY2025$1.42B15.4%$50.5M$0.31
Q1 FY2025$1.33B16.3%$46.7M$0.28
Q4 FY2024$1.35B19.7%$60.1M$0.35
Q3 FY2024$1.28B17.0%$53.9M$0.31
Q2 FY2024$1.23B14.8%$53.0M$0.30

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNasdaq
SectorHealthcare
SIC industryServices-Home Health Care Services
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ1 FY2026 (ended March 31, 2026)
Oldest indexed filing2013
SEC CIK1014739

Selected SEC filings

10-Q2026-07-29
View on EDGAR →
10-Q2026-04-30
View on EDGAR →
8-K2026-07-29
View on EDGAR →
8-K2026-05-22
View on EDGAR →
8-K2026-05-12
View on EDGAR →
8-K2026-05-05
View on EDGAR →

Largest Healthcare peers

All Healthcare companies →

Monitor OPCH

Get an alert when Option Care Health files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor OPCH free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.